Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00423150
Status:
TERMINATED
Last Update Posted:
2017-06-08
First Post:
2006-11-30
Brief Title:
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers Study P04273AM2TERMINATED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase 2 Study of Temozolomide SCH 52365 in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase MGMT Promoter
Status:
TERMINATED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is proposed to evaluate the efficacy and safety of temozolomide an oral anti-cancer agent in a participant population selected for a biomarker Participants with colorectal cancer non-small-cell lung cancer head and neck cancer or esophageal cancer will be included
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None